Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Foley

Showing results (101-110 of 185) with videos related to

Pageof 19
Sort By:
Archives of Dermatology|May 21, 2008
Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indicationBronwyn Williams, Daina Vanags, Stephen Hall, et al.
Multiple Sclerosis and Related Disorders|May 16, 2022
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosisStella A Glasmacher, Patrick Ka Kearns, Zackary Hassan, et al.
Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
American Journal of Clinical Dermatology|November 13, 2018
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesApril W Armstrong, Kristian Reich, Peter Foley, et al.
Acta Dermato-Venereologica|February 3, 2016
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque PsoriasisJeffrey M Sobell, Peter Foley, Darryl Toth, et al.
The Journal of Dermatological Treatment|May 11, 2016
Adherence to topical therapies in actinic keratosis: A literature reviewPeter Foley, Eggert Stockfleth, Ketty Peris, et al.
The Australasian Journal of Dermatology|July 13, 2016
The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian settingMarius Rademaker, Monisha Gupta, Megan Andrews, et al.
ACS Biomaterials Science & Engineering|October 4, 2023
Layer-by-Layer Analysis of <i>In Vitro</i> Skin ModelsElizabeth Footner, Kate Firipis, Emily Liu, et al.
The Australasian Journal of Dermatology|September 20, 2022
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian settingPeter Foley, Yves A Kerdraon, John P Hogden, et al.
Pageof 19

Showing results (101-110 of 185) with videos related to

Sort By:
Pageof 19
Archives of Dermatology|May 21, 2008
Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indicationBronwyn Williams, Daina Vanags, Stephen Hall, et al.
Multiple Sclerosis and Related Disorders|May 16, 2022
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosisStella A Glasmacher, Patrick Ka Kearns, Zackary Hassan, et al.
Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
American Journal of Clinical Dermatology|November 13, 2018
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesApril W Armstrong, Kristian Reich, Peter Foley, et al.
Acta Dermato-Venereologica|February 3, 2016
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque PsoriasisJeffrey M Sobell, Peter Foley, Darryl Toth, et al.
The Journal of Dermatological Treatment|May 11, 2016
Adherence to topical therapies in actinic keratosis: A literature reviewPeter Foley, Eggert Stockfleth, Ketty Peris, et al.
The Australasian Journal of Dermatology|July 13, 2016
The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian settingMarius Rademaker, Monisha Gupta, Megan Andrews, et al.
ACS Biomaterials Science & Engineering|October 4, 2023
Layer-by-Layer Analysis of <i>In Vitro</i> Skin ModelsElizabeth Footner, Kate Firipis, Emily Liu, et al.
The Australasian Journal of Dermatology|September 20, 2022
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian settingPeter Foley, Yves A Kerdraon, John P Hogden, et al.
Pageof 19